Publications

Lu J, Li XQ, Chen PP, Zhang JX, Liu L, Wang GH, Liu XQ, Jiang TT, Wang MY, Liu WT, Ruan XZ, Ma KL(*). Activation of acetyl-CoA synthetase 2 mediates kidney injury in diabetic nephropathy. JCI Insight. 2023 Oct 23;8(20): e165817.

Lu J, Li XQ, Chen PP, Zhang JX, Li L, Wang GH, Liu XQ, Jiang CM, Ma KL(*). Acetyl-CoA synthetase 2 promotes diabetic renal tubular injury in mice by rewiring fatty acid metabolism through SIRT1/ChREBP pathway. Acta Pharmacol Sin. 2024 Feb;45(2):366-377.

Chen PP, Zhang JX, Li XQ, Li L, Wu QY, Liu L, Wang GH, Ruan XZ, Ma KL(*).  Outer membrane vesicles derived from gut microbiota mediate tubulointerstitial inflammation: a potential new mechanism for diabetic kidney disease. Theranostics. 2023 Jul 9;13(12):3988-4003.

Wu QY, Liu BC, Ruan XZ, Ma KL(*). Intestinal microbiota-derived membrane vesicles and their role in chronic kidney disease. Biochim Biophys Acta Mol Basis Dis. 2022 Oct 1;1868(10):166478. 

Liu XQ, Jiang TT, Wang MY, Liu WT, Huang Y, Huang YL, Jin FY, Zhao Q, Wang GH, Ruan XZ, Liu BC, Ma KL(*). Using Machine Learning to Evaluate the Role of Microinflammation in Cardiovascular Events in Patients With Chronic Kidney Disease. Front Immunol. 2022 Jan 10; 12:796383. 

Lu J, Chen PP, Zhang JX, Li XQ, Wang GH, Yuan BY, Huang SJ, Liu XQ, Jiang TT, Wang MY, Liu WT, Ruan XZ, Liu BC, Ma KL(*). GPR43 activation-mediated lipotoxicity contributes to podocyte injury in diabetic nephropathy by modulating the ERK/EGR1 pathway. Int J Biol Sci. 2022 Jan 1;18(1):96-111.

Lu J, Chen PP, Zhang JX, Li XQ, Wang GH, Yuan BY, Huang SJ, Liu XQ, Jiang TT, Wang MY, Liu WT, Ruan XZ, Liu BC, Ma KL^(*). GPR43 deficiency protects against podocyte insulin resistance in diabetic nephropathy through the restoration of AMPKα activity. Theranostics. 2021 Mar 4;11(10):4728-4742.

Lu CC, Hu ZB, Wang R, Hong ZH, Lu J, Chen PP, Zhang JX, Li XQ, Yuan BY, Huang SJ, Ruan XZ, Liu BC, Ma KL^(*). Gut microbiota dysbiosis-induced activation of the intrarenal renin-angiotensin system is involved in kidney injuries in rat diabetic nephropathy. Acta Pharmacol Sin 2020 Aug;41(8):1111-1118.  

Hu ZB, Lu J, Chen PP, Lu CC, Zhang JX, Li XQ, Yuan BY, Huang SJ, Ruan XZ, Liu BC, Ma KL^(*). Dysbiosis of intestinal microbiota mediates tubulointerstitial injury in diabetic nephropathy via the disruption of cholesterol homeostasis. Theranostics 2020;10(6):2803-2816.  

Wang GH, Ma KL^(*), Zhang Y, Hu ZB, Liu L, Lu J, Chen PP, Lu CC, Ruan XZ, Liu BC. Platelet microparticles contribute to aortic vascular endothelial injury in diabetes via the mTORC1 pathway. Acta Pharmacol Sin. 2019 Apr;40(4):468-476.

Wang GH, Lu J, Ma KL^(*), Zhang Y, Hu ZB, Chen PP, Lu CC, Zhang XL, Liu BC. The Release of Monocyte-Derived Tissue Factor-Positive Microparticles Contributes to a Hypercoagulable State in Idiopathic Membranous Nephropathy. J Atheroscler Thromb. 2019 Jun 1;26(6):538-546.

Zhang Y, Ma KL^(*), Gong YX, Wang GH, Hu ZB, Liu L, Lu J, Chen PP, Lu CC, Ruan XZ, Liu BC. Platelet Microparticles Mediate Glomerular Endothelial Injury in Early Diabetic Nephropathy. J Am Soc Nephrol. 2018;29(11):2671-2695.  

Hu ZB, Ma KL^(*), Zhang Y, Wang GH, Liu L, Lu J, Chen PP, Lu CC, Liu BC. Inflammation-activated CXCL16 pathway contributes to tubulointerstitial injury in mouse diabetic nephropathy. Acta Pharmacol Sin. 2018;39(6):1022-1033.  

Lu CC, Ma KL^(*), Ruan XZ, Liu BC. The Emerging Roles of Microparticles in Diabetic Nephropathy. Int J Biol Sci. 2017 Sep 5;13(9):1118-1125.  

Wu Y, Ma KL^(*), Zhang Y, Wen Y, Wang GH, Hu ZB, Liu L, Lu J, Chen PP, Ruan XZ, Liu BC. Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contributes to non-alcoholic fatty liver disease. Liver Int. 2016; 36(10):1525-34.  

Zhang Y, Ma KL^(*), Ruan XZ, Liu BC. Dysregulation of the Low-Density Lipoprotein Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury. Int J Biol Sci. 2016; 12(5):569-79.

Zhang Y, Ma KL^(*), Liu J, Wu Y, Hu ZB, Liu L, Liu BC. Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy. Am J Physiol Endocrinol Metab. 2015; 308(12): E1140-8.

Zhang Y, Ma KL^(*), Liu J, Wu Y, Hu ZB, Liu L, Lu J, Zhang XL, Liu BC. Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy. Acta Diabetol. 2015; 52(6):1045-56.

Liu J, Ma KL^(*), Zhang Y, Wu Y, Hu ZB, Lv LL, Tang RN, Liu H, Ruan XZ, Liu BC. Activation of mTORC1 disrupted LDL receptor pathway: a potential new mechanism for the progression of non-alcoholic fatty liver disease. Int J Biochem Cell Biol. 2015; 61: 8-19.   

Ma KL^(*), Zhang Y, Liu J, Wu Y, Hu ZB, Ruan XZ, Liu BC. Establishment of an Inflamed Animal Model of Diabetic Nephropathy. Int J Biol Sci 2014; 10(2): 149-159.  

Ma KL, Liu J, Wang CX, Ni J, Zhang Y, Wu Y, Lv LL, Ruan XZ, Liu BC. Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation. Cardiovasc Res 2013; 100(3):450-60.

Ma KL, Varghese Z, Ku Y, Powis SH, Chen Y, Moorhead JF, *Ruan XZ. Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2010; 298(6):H1646-51.  

Ma KL, *Ruan XZ, Powis SH, Chen YX, Moorhead JF, and Varghese Z. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology 2008; 48 (3):770-81.

Ma KL, *Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia. Transplantation 2007; 84(8):1029-36.  

Ma KL, *Ruan XZ, Powis SH, Moorhead JF, and Varghese Z. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2007; 292 (6):H2721-8.